REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing...
REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing...
REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing...
DUBLIN and BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the...
DUBLIN and BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the...
DUBLIN and BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the...
MELVILLE, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine...
MELVILLE, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine...
MELVILLE, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine...
Recent agreements with two additional U.S. mental health providers bring total to four in 2025 Strategy seeks to drive long-term...
Recent agreements with two additional U.S. mental health providers bring total to four in 2025 Strategy seeks to drive long-term...
Recent agreements with two additional U.S. mental health providers bring total to four in 2025 Strategy seeks to drive long-term...
Korea’s First Bacteriophage IND Approved by the Ministry of Food and Drug Safety – Phase 1 Trial to Begin in...
Korea’s First Bacteriophage IND Approved by the Ministry of Food and Drug Safety – Phase 1 Trial to Begin in...
Korea’s First Bacteriophage IND Approved by the Ministry of Food and Drug Safety – Phase 1 Trial to Begin in...
RANCHO CUCAMONGA, CA / ACCESS Newswire / October 27, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will...
Advances made in preclinical pipeline addressing neurodegenerative diseasesEvotec receives US$ 25 m payment to support continued progression of joint programs...
Newly uncovered DEA agreements confirm what MMJ BioPharma Cultivation has argued for years - that the agency's own rules make...
Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolismRobust...
NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (emapalumab) data showed response rates in...